Fig. 3.

Disappearance of FANCD2 is mediated by the caspases and not proteasome-dependent pathway. A: WT fibroblast or FANCG-deficient cells were treated with 100 µM CDDP for 6 h and harvested for immunoblot analysis. Where indicated, 25 µM of a proteasome inhibitor (ALLN) was added at the time of CDDP treatment. B: WT fibroblast cells were treated with 0 or 100 µM CDDP for 16 h and harvested for protein analysis by immunoblot. Where indicated (lane 3), 10 µM of caspase inhibitor (Z-VAD-FMK) was treated at the time of CDDP treatment. DNA-PKcs and PARP were included as positive controls, while Ku70 was used as a loading control.